544716-08-7

Basic information

• Product Name: 4-MERCAPTO-6-(TRIFLUOROMETHYL)QUINOLINE
• Synonyms: BUTTPARK 13\01-65;4-MERCAPTO-6-(TRIFLUOROMETHYL)QUINOLINE;6-(Trifluoromethyl)quinoline-4-thiol
• CAS NO: 544716-08-7
• Molecular Formula: C10H6F3NS
• Molecular Weight: 229.22
• Mol File: 544716-08-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 307.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.407±0.06 g/cm3(Predicted)
• PKA: 0.20±0.30(Predicted)
• CAS DataBase Reference: 4-MERCAPTO-6-(TRIFLUOROMETHYL)QUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-MERCAPTO-6-(TRIFLUOROMETHYL)QUINOLINE(544716-08-7)
• EPA Substance Registry System: 4-MERCAPTO-6-(TRIFLUOROMETHYL)QUINOLINE(544716-08-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 544716-08-7(Hazardous Substances Data)

Upstream product

• 49713-51-1 4-hydroxy-6-(trifluoromethyl)quinoline 
• 49713-56-6 4-chloro-6-(trifluoromethyl)quinoline 

Relevant articles and documents

CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF

The present invention relates to a cycloalkyl acid derivative, a preparation method thereof, and a pharmaceutical application thereof, and in particular, the present invention relates to a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level, wherein definitions of substituent groups in general formula (I) are the same as definitions in the specifications.

Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model

This Letter describes the discovery of a series of potent inhibitors of Human Uric Acid Transporter 1 (hURAT1). Lead generation and optimization via 3D pharmacophore analysis resulted in compound 41. With an IC50 of 33.7 nM, 41 also demonstrated good oral bioavailability in rat (74.8%) and displayed a consistent PK profile across all species tested (rat, dog and monkey).